<DOC>
	<DOCNO>NCT00118456</DOCNO>
	<brief_summary>AEE788 orally active , reversible , small-molecule , multi-targeted kinase inhibitor potent inhibitory activity ErbB VEGF receptor family tyrosine kinase . It IC50 le 100 nM p-EGFR , p-ErbB2 , p-KDR ( VEGFR2 ) . This study ass safety , pharmacokinetic ( PK ) /pharmacodynamic ( PD ) profile clinical activity AEE788 advance cancer .</brief_summary>
	<brief_title>Study Oral AEE788 Adults With Advanced Cancer</brief_title>
	<detailed_description />
	<criteria>Histologically confirm solid tumor Adequate hematologic , renal hepatic function Age ≥ 18 year Karnofsky performance status score ≥ 70 % Life expectancy ≥ 12 week Active brain metastasis Peripheral neuropathy &gt; grade 2 Diarrhea &gt; grade 1 Gastrointestinal ( GI ) dysfunction Compromised cardiac function Concurrent severe and/or uncontrolled medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Advanced cancer</keyword>
	<keyword>EGFR</keyword>
	<keyword>Her2</keyword>
	<keyword>VEGFR</keyword>
</DOC>